Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01946373 | T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma | unknown | Phase 1 | 20 | Karolinska University HospitalOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05062096 | Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence(NAKIMEL) | unknown | N/A | 220 | Assistance Publique - Hôpitaux de ParisOTHER | 0 |
| Oct 4, 2022 |
| clinicaltrials |
| NCT04913025 | REduced Frequency ImmuNE Checkpoint Inhibition in Cancers(REFINE) | unknown | Phase 2 | 160 | University College, LondonOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT05510466 | Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis | unknown | — | 18 | University Hospital, MontpellierOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT03934827 | MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour(MICROBIOME) | unknown | Phase 1 | 120 | Imperial College LondonOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05467137 | Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG(MelanooMSOT) | unknown | Phase 4 | 10 | University Medical Center GroningenOTHER | 0 | Jul 20, 2022 | clinicaltrials |
| NCT05445752 | Conservative Nodal Surgery (Node-picking) of Patients With Stage III Melanoma With Low-burden of Nodal Disease (MELCONSURG MULTICENTRE COHORT) | unknown | — | 68 | Hospital Universitario Virgen MacarenaOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05426317 | Exploratory Interventional Study of Prognostic Serum Biomarkers of Cancer Progression(Onco-PDL1s/B2M) | unknown | N/A | 100 | University Hospital, Clermont-FerrandOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05402059 | Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice(ISABELLA) | unknown | — | 1,570 | MelanomaPRO, RussiaOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT04353050 | Atypical MOLes and Melanoma Early Detection Study (MoleMed)(MoleMed) | unknown | N/A | 350 | Russian Academy of Medical SciencesOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT05402046 | Clinical vAlidation of a MobilE appLication ("ProRodinki") in the Assessment of the maLignant skIn neoplAsms(CAMELLIA) | unknown | N/A | 605 | MelanomaPRO, RussiaOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05171374 | pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE(RATIONALE) | unknown | — | 500 | MelanomaPRO, RussiaOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT03374839 | Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients(Nivo-TIL) | unknown | Phase 1 / Phase 2 | 11 | Nantes University HospitalOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT03385486 | Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors | unknown | Phase 1 | 72 | Taiga Biotechnologies, Inc.INDUSTRY | 1 | May 3, 2022 | clinicaltrials |
| NCT05114603 | A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation | unknown | Phase 2 | 30 | Shanghai Henlius BiotechINDUSTRY | 1 | May 3, 2022 | clinicaltrials |
| NCT05340543 | Ex-vivo Examination of Excisions of Skin Tumors by Confocal Optical Coherence Tomography (LC-OCT) With Integrated Dermoscopy and Comparison With Histology (DERMOCTAV)(DERMOCTAV) | unknown | — | 150 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT02437279 | Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients(OpACIN) | unknown | Phase 1 | 20 | The Netherlands Cancer InstituteOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT02076646 | A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma | unknown | Phase 1 / Phase 2 | 96 | Philogen S.p.A.INDUSTRY | 2 | Apr 14, 2022 | clinicaltrials |
| NCT03161756 | Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma(CHARLI) | unknown | Phase 1 / Phase 2 | 72 | Melanoma and Skin Cancer Trials LimitedOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT02784366 | GI Complications in Cancer Immunotherapy Patients | unknown | — | 100 | Massachusetts General HospitalOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT02637531 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | unknown | Phase 1 | 219 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05119829 | Melanoma: Genomic Profiles, Molecular Markers and Therapeutic Implications | unknown | — | 80 | Hellenic Cooperative Oncology GroupOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02994498 | Safety and Efficacy of DCB-BO1301 in Advanced Melanoma | unknown | Phase 1 / Phase 2 | 33 | Chung Mei Biopharma Co., LtdINDUSTRY | 0 | Mar 18, 2022 | clinicaltrials |
| NCT05274438 | Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut | unknown | Phase 2 | 37 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT05235607 | Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors | unknown | Phase 1 | 60 | Sichuan UniversityOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT05180851 | Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study(YSCH-01) | unknown | Early Phase 1 | 28 | Shanghai Fengxian District Central HospitalOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT04180995 | Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma | unknown | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 31, 2022 | clinicaltrials |
| NCT04462965 | Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study | unknown | Phase 2 | 294 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT05190185 | A Clinical Trial of TAA06 Injection in Advanced Solid Tumors | unknown | Phase 1 | 18 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jan 13, 2022 | clinicaltrials |
| NCT03715985 | Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)(NeoPepVac) | unknown | Phase 1 / Phase 2 | 12 | Herlev HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05179174 | The Role of Genetic Mutations and of Circulating mRNAs in Uveal Melanoma | unknown | — | 102 | University of CataniaOTHER | 2 | Jan 5, 2022 | clinicaltrials |
| NCT04025424 | Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519)(ICIPRESIST19) | unknown | — | 350 | Russian Academy of Medical SciencesOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT05103891 | Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations | unknown | Phase 1 | 14 | Pierre Fabre MedicamentINDUSTRY | 1 | Dec 1, 2021 | clinicaltrials |
| NCT05120024 | Multicenter Study of Safety and Efficacy of Prolgolimab in Patients With Advanced Melanoma in Routine Clinical Practice(FORA) | unknown | — | 350 | MelanomaPRO, RussiaOTHER | 1 | Nov 15, 2021 | clinicaltrials |
| NCT05117138 | Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors | unknown | Phase 1 / Phase 2 | 39 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Nov 11, 2021 | clinicaltrials |
| NCT03291002 | Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC | unknown | Phase 1 | 98 | CureVacINDUSTRY | 5 | Nov 4, 2021 | clinicaltrials |
| NCT05104801 | Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma | unknown | Phase 2 | 37 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT00553618 | Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients(DTIC) | unknown | Phase 2 | 160 | University of LouisvilleOTHER | 1 | Oct 29, 2021 | clinicaltrials |
| NCT05097378 | Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma(PREMIUM) | unknown | Phase 2 | 45 | CCTU- Cancer ThemeOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT03925350 | Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation | unknown | Phase 2 | 41 | California Pacific Medical Center Research InstituteOTHER | 1 | Oct 22, 2021 | clinicaltrials |
| NCT05089188 | PRAME Immunohistochemistry as an Adjunct for Evaluating Ambiguous Melanocytic Proliferation(ANTIPRAME) | unknown | — | 55 | University Hospital, Strasbourg, FranceOTHER | 1 | Oct 22, 2021 | clinicaltrials |
| NCT05070221 | Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis | unknown | Phase 1 | 30 | Peking University Cancer Hospital & InstituteOTHER | 0 | Oct 7, 2021 | clinicaltrials |
| NCT05068453 | Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis | unknown | Phase 1 | 15 | Peking University Cancer Hospital & InstituteOTHER | 0 | Oct 5, 2021 | clinicaltrials |
| NCT05047276 | Phase I/II Study of AloCelyvir in Patients With Metastatic Uveal Melanoma(PULSE-UM) | unknown | Phase 1 / Phase 2 | 16 | José María Piulats RodríguezOTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT05009446 | Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM(SNMM) | unknown | Early Phase 1 | 28 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT04521075 | A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC | unknown | Phase 1 / Phase 2 | 42 | Ella Therapeutics LtdINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT04979585 | Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma | unknown | Phase 2 | 66 | Di WuOTHER | 1 | Aug 3, 2021 | clinicaltrials |
| NCT04177056 | Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief(SOLAR-P) | unknown | N/A | 40 | Hamilton Health Sciences CorporationOTHER | 1 | Aug 2, 2021 | clinicaltrials |
| NCT04871334 | Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma | unknown | Phase 1 | 76 | Shandong TheraWisdom Biopharma Co., Ltd.INDUSTRY | 1 | Jul 23, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Oct 4, 2022source: clinicaltrials